The FDA recently approved a new rapid-acting mealtime insulin called Lyumjev, which is absorbed into the body more quickly than Humalog and is designed to target post-meal spikes and reduce A1c.
read more →
Dr. Edelman offers a solution for “Foot to Floor” phenomenon, which is a very common situation in people with diabetes who are on insulin, and occurs when blood sugars rise upon waking.
read more →
Did you know that certain aspects of type 2 diabetes can change over time? Even if you’ve had years of great blood sugar control, you still may need to make some medication adjustments down the road, and that’s totally normal.
read more →
A common misconception for people with type 2 diabetes is thinking they’ve somehow failed if they need to go on insulin. Nothing could be further from the truth, and insulin-pump therapy is a great option to help people reach their blood sugar goals.
read more →
NeedyMeds is a 501(c)(3) national non-profit information source that connects people to programs that will help them afford their medications and other healthcare costs.
read more →
Fiasp, a rapid-acting insulin for people with type 2 or type 2 diabetes, was recently approved for use in insulin pumps and provides another option for people to help improve their post-meal blood sugars.
read more →
Companion Medical, makers of the first FDA approved smart insulin pen, recently announced their Bluetooth-enabled InPen is now available in retail pharmacies nationwide. These smart pens offer a variety of benefits with very few downsides.
read more →
There are a lot of misconceptions around DKA, or diabetic ketoacidosis. It’s a common but very serious acute complication that develops when someone who is insulin dependent loses access to insulin (your pump line falls out, etc). Drs. Edelman and Pettus explain the causes, symptoms, and treatment.
read more →
Inhaled insulin Afrezza is a great option for a lot of people living with type 1 and type 2 diabetes because it doesn’t involve shots and has a rapid on-rapid off effect. The makers of Afrezza just announced a direct purchase program to help people get it for as little as $4 a day.
read more →
A new oral medication for T1D is awaiting FDA approval, and it’s shown fewer highs, fewer lows, and more predictable insulin dosing in recent studies.
read more →
